Alkermes plc
Research Alkermes plc (ALKS) on Bullrun: valuation model: 52.3% overvalued, market cap USD 8.76B, P/E 58.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALKS
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal52.3% overvalued
- Market capUSD 8.76B
- P/E58.4
- Financial periodFY2025
- RevenueUSD 1.48B
- Revenue growth-5.2%
- Net incomeUSD 241.70M
- Free cash flowUSD 480.33M
- Gross margin86.7%
Valuation Snapshot
Bullrun's latest valuation model marks Alkermes plc as 52.3% overvalued; latest market cap is USD 8.76B; P/E is 58.4.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Frequently asked questions
Is Alkermes plc overvalued or undervalued?
Bullrun's valuation model currently marks Alkermes plc as 52.3% overvalued.
What is Alkermes plc's market cap?
Alkermes plc's market capitalization is USD 8.76B.
What is Alkermes plc's P/E ratio?
Alkermes plc's price-to-earnings (P/E) ratio is 58.4.
What does Alkermes plc do?
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.